Financial News Feed

AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

Read more

No summary available....

Read more

ACRX earnings call for the period ending March 31, 2019....

Read more

The pharma announced first-quarter 2019 operating results....

Read more

Earnings movers dominate premarket losers
01:25pm, Thursday, 09'th May 2019
No summary available....

Read more

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q1 2019 Earnings Conference Call May 08, 2019 04:30 PM ET Company Participants Raffi Asadorian - Chief Financial Offi...

Read more

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 26.09% and -68.64%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?...

Read more

No summary available....

Read more

We expect AcelRx (ACRX) to provide update on the launch of its newly approved drug DSUVIA, when it reports first-quarter 2019 results....

Read more

No summary available....

Read more

FRED, UBS and MT among premarket losers
01:21pm, Monday, 06'th May 2019
No summary available....

Read more

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

Read more

No summary available....

Read more

No summary available....

Read more

No summary available....

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank